Genomic Technology Helped Drive 52-Percent Jump In R&D Success at Big Pharma; More Business Likely | GenomeWeb

Big pharma may have genomic tool vendors to thank in part for a recent surge in R&D productivity — and it could return the favor with greater technology investment.

After declining more than 20 percent from the mid-1990s to the early-2000s, the rate at which new candidates at the 10 biggest drug makers entered clinical testing has increased 52 percent in recent years, according to a report released last week from the Tufts Center for the Study of Drug Development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.